ClinicalTrials.gg
CompletedNCT05490511Updated Sep 30, 2026Results posted

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

A Phase 1 interventional study of Tacrolimus single dose and Epidiolex single dose in CBD, Transplant Complication and Kidney Disease, Chronic, sponsored by Indiana University. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Indiana University · Phase 1, Interventional, and Supportive care

How we know

Updated Sep 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Renal Insufficiency, Chronic by Indiana University — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency, Chronic · Indiana University.

Enrollment
5th of 10
57 · median 37
Started
2022
the only one that year
Phase 1
Only one
of the 12
Registered
10th of 12
by date

Among the 12 studies in Renal Insufficiency, Chronic by Indiana University, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1, and was the 10th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

2 of the 12 studies in Renal Insufficiency, Chronic by Indiana University are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency, Chronic by Indiana University, or all of them as a file.
02

Study summary

The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.

Read the detailed description

The commercial availability of cannabidiol, or CBD oil, has increased in the United Stated and this supplement has the potential to cause a variety of drug-drug interactions, including in solid organ transplant recipients who receive tacrolimus to prevent rejection. Through a series of pharmacokinetic and pharmacodynamics assays, this proposal will identify gene-drug and drug-drug interactions (DDI), including those that place transplant recipients at risk for increased toxicity related to their immunosuppression. The information learned in these studies will help to inform practitioners as to whether cannabidiol needs to be avoided in transplant recipients and how to appropriately adjust doses of CBD and immunosuppression in order to improve health outcomes and long-term treatment success in this high-risk population.

03

Conditions studied

  • CBD
  • Transplant Complication
  • Kidney Disease, Chronic

Keywords

  • cannabidiol
  • tacrolimus
  • CYP3A5
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75
  • Are judged healthy enough to participate as determined by and decided from a pre-enrollment screening session that includes medical history and laboratory tests such as blood and urine tests, and electrocardiography ().
  • Agree to refrain from taking any prescription medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of the study drugs at least 2 weeks prior to the start of the study and until study completion.
  • Are willing to commit the time requested for this study
  • Are willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 26 days).

Additional Criteria for the Healthy volunteer study:

  • Have a above 60 ml/min/1.73m2 with proteinuria less than 0.3 grams by urine protein to creatinine ratio or 24 hour urine collection

Additional Criteria for the CKD study:

  • Have either:
  • A GFR less than or equal to 60 ml/min/1.73m2 or
  • The presence of greater than 0.3 grams of proteinuria by urine protein to creatinine ratio or 24 hour urine collection, but less than 3.5 gm of nephrotic range proteinuria as hypoalbuminemia may impact protein binding.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Have history of intolerance, allergic reactions (e.g. rash) or other forms of to any of the study medications (tacrolimus or cannabidiol);
  • Are currently taking sedative agents, including agents for insomnia
  • Are underweight ( (BMI) less than 18.5) or overweight [body mass index (BMI) greater than 35]
  • Have a positive pregnancy serum or urine test obtained just prior to each study, or are breast feeding
  • Are night shift workers
  • Are on dialysis
  • Have compromised liver function as defined by pre-screening , and ALT testing including any elevation of bilirubin or AST/ALT more than 2x the .
  • Are not willing to refrain from smoking or use of marijuana for at least two weeks prior to and until the completion of the study
  • Have a \< 10.0 g/dL
  • Have gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs
  • Have a history of or current seizure disorder
  • Are currently on or are immunosuppressed.
  • Are recipients of a current allograft (heart, kidney, pancreas, liver, intestine, lung, stem cell transplant).
  • Have baseline readings that are abnormal that could place the patient at the high risk.
  • Have alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse, including opioids, or have used tobacco products or marijuana within the past three months, and are unwilling or unable to stop taking these medications two weeks prior to and during the entire study period
  • Have participated in a research study involving intensive blood sampling or have donated blood within the past two months
  • Had an unplanned hospitalization in the last 6 months or two or more unplanned hospitalizations in the last 2 years.
  • Are taking prescription medications, that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of /5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol). Interactions will be screened according to the Flockhart table.
  • Are taking over-the-counter medications, herbal or dietary supplements, and alternative medicines that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol) that the subject is unwilling or unable to stop over the course of the study. Interactions will be screened according to the Flockhart table.
  • Are students under supervision of any of the study investigators.
  • Cannot commit the time requested for this study.
  • Have a known CYP3A4 *22/*22 genotype
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Active comparator
    CYP3A5 expressers without chronic kidney disease

    Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose

  • Active comparator
    CYP3A5 non-expressers without chronic kidney disease

    Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose

  • Active comparator
    CYP3A5 expressers with chronic kidney disease

    Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose

  • Active comparator
    CYP3A5 non-expressers with chronic kidney disease

    Drug: Tacrolimus single dose · Drug: Epidiolex single dose · Drug: Epidiolex steady-state and tacrolimus single dose

Interventions

  • DrugTacrolimus single dose

    5 mg once

    Also known as: Period 1

  • DrugEpidiolex single dose

    Epidiolex 5 mg/kg

    Also known as: Period 2

  • DrugEpidiolex steady-state and tacrolimus single dose

    Drug page: PNU-100480Studies of PNU-100480PNU-100480 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

    Also known as: Period 3

06

What researchers measure

Primary outcomes

  1. The AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone

    The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Tacrolimus whole blood concentrations were measured at 0, 20, 40, and 60 minutes and 2, 4, 6, 12, 24, 48, and/or 72 hours.

    Time frame: 27 days

Secondary outcomes

  1. Cell Viability Ratio

    The hypothesis tested is that cannabidiol will reduce immune cell proliferation between Period 1 and Period 3. There is no comparison between CYP3A5 expressor groups intended for this outcome measure. Period 1 (pre-CBD or baseline measurement) and Period 3 (post-CBD or steady-state cannabidiol) will be compared in a subset of individuals undergoing this phenotyping. Cell viability was measured in peripheral blood mononuclear cells using CellTiter-Glo (Promega Corp., catalog G7570) on 96-well plates to quantify cell proliferation by adenosine triphosphate (ATP) detection using a Spectramax M5 system coupled with SoftMax Pro 5.2 (Molecular Devices). Values were calculated as a unitless ratio of luminescence (ATP detection) in the stimulated (CD3/CD28) condition normalized by the non-stimulated (No CD3/CD28) condition.

    Time frame: 27 days

07

Results

Posted Sep 30, 2026

Participant flow

We will recruit a mix of individuals with and without CKD because this is representative of the transplant population. We will also recruit a mix of CYP3A5 expressors and non-expressors. Patients who have given consent to be recontacted in prior studies or as part of the Indiana Biobank will be called or sent a letter for recruitment. Advertising and recruiting outside of these already genotyped pools of subjects will also be done. Our main recruitment site is the Indiana University campus.

Participant flow — Overall Study
MilestoneCYP3A5 Expressers Without Chronic Kidney DiseaseCYP3A5 Expressers With Chronic Kidney DiseaseCYP3A5 Non-expressers Without Chronic Kidney DiseaseCYP3A5 Non-expressers With Chronic Kidney DiseaseNon-Genotyped
Started10423713
Completed1042070
Not completed003013

Outcome measures

PrimaryThe AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone

The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Tacrolimus whole blood concentrations were measured at 0, 20, 40, and 60 minutes and 2, 4, 6, 12, 24, 48, and/or 72 hours.

Time frame:
27 days
Reported as:
Geometric mean · AUC0-Infinity Ratio
The AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone
AUC0-Infinity RatioCYP3A5 Non-expressers Without Chronic Kidney Disease (Who Completed the Study in Its Entirety)CYP3A5 Expressers Without Chronic Kidney Disease (Who Completed the Study in Its Entirety)CYP3A5 Non-expressers With Chronic Kidney Disease (Who Completed the Study in Its Entirety)CYP3A5 Expressers With Chronic Kidney Disease (Who Completed the Study in Its Entirety)
The AUC0-Infinity Ratio of Tacrolimus With Cannabidiol Divided by Tacrolimus Alone2.9 (2.6 to 3.1)3.8 (3.1 to 4.7)2.5 (2.0 to 3.0)2.4 (0.8 to 6.7)
SecondaryCell Viability Ratio

The hypothesis tested is that cannabidiol will reduce immune cell proliferation between Period 1 and Period 3. There is no comparison between CYP3A5 expressor groups intended for this outcome measure. Period 1 (pre-CBD or baseline measurement) and Period 3 (post-CBD or steady-state cannabidiol) will be compared in a subset of individuals undergoing this phenotyping. Cell viability was measured in peripheral blood mononuclear cells using CellTiter-Glo (Promega Corp., catalog G7570) on 96-well plates to quantify cell proliferation by adenosine triphosphate (ATP) detection using a Spectramax M5 system coupled with SoftMax Pro 5.2 (Molecular Devices). Values were calculated as a unitless ratio of luminescence (ATP detection) in the stimulated (CD3/CD28) condition normalized by the non-stimulated (No CD3/CD28) condition.

Time frame:
27 days
Reported as:
Mean · luminescence/luminescence
Cell Viability Ratio
luminescence/luminescencePeriod 1Period 3
Cell Viability Ratio2.04 ± 0.5741.5 ± 0.571

Adverse events

Collected over from enrollment/consent until end of follow-up (approximately 28 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CYP3A5 Expressers Without Chronic Kidney Disease0/10 (0%)0/10 (0%)10/10 (100%)
CYP3A5 Non-expressers Without Chronic Kidney Disease0/23 (0%)0/23 (0%)21/23 (91.3%)
CYP3A5 Expressers With Chronic Kidney Disease0/4 (0%)0/4 (0%)4/4 (100%)
CYP3A5 Non-expressers With Chronic Kidney Disease0/7 (0%)0/7 (0%)7/7 (100%)
Non-Genotyped0/13 (0%)0/13 (0%)0/13 (0%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventCYP3A5 Expressers Without Chronic Kidney DiseaseCYP3A5 Non-expressers Without Chronic Kidney DiseaseCYP3A5 Expressers With Chronic Kidney DiseaseCYP3A5 Non-expressers With Chronic Kidney DiseaseNon-Genotyped
ConstipationGastrointestinal disorders0/1019/231/44/70/13
DiarrheaGastrointestinal disorders6/1019/232/44/70/13
Sleepiness/FatigueNervous system disorders7/1013/233/45/70/13
Poor SleepNervous system disorders3/109/232/44/70/13
Decreased AppetiteGastrointestinal disorders5/107/230/42/70/13
RashSkin and subcutaneous tissue disorders0/105/232/40/70/13
HeadacheNervous system disorders3/102/230/42/70/13
LethargicNervous system disorders0/100/231/40/70/13
NightmaresNervous system disorders0/100/231/41/70/13
LightheadedNervous system disorders0/100/231/40/70/13

Baseline characteristics

Consented patients counted, some participants may have been excluded after the screening process due to failing some aspect of the required tests done (for example: failed urine drug screen or high BMI). Participants may have also chosen to exclude themselves after screening for various reasons (for example: lack of time to attend study visits)

Age, Continuous
Age, Continuous(Years)CYP3A5 Expressers Without Chronic Kidney DiseaseCYP3A5 Expressers With Chronic Kidney DiseaseCYP3A5 Non-expressers Without Chronic Kidney DiseaseCYP3A5 Non-expressers With Chronic Kidney DiseaseNon-GenotypedTotal
Mean41.30 ± 19.5666.75 ± 18.2238.65 ± 10.9563.71 ± 14.6852.69 ± 9.1347.37 ± 16.61
Sex: Female, Male
Sex: Female, Male(Participants)CYP3A5 Expressers Without Chronic Kidney DiseaseCYP3A5 Expressers With Chronic Kidney DiseaseCYP3A5 Non-expressers Without Chronic Kidney DiseaseCYP3A5 Non-expressers With Chronic Kidney DiseaseNon-GenotypedTotal
Female53186941
Male5151416
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CYP3A5 Expressers Without Chronic Kidney DiseaseCYP3A5 Expressers With Chronic Kidney DiseaseCYP3A5 Non-expressers Without Chronic Kidney DiseaseCYP3A5 Non-expressers With Chronic Kidney DiseaseNon-GenotypedTotal
American Indian or Alaska Native000000
Asian102014
Native Hawaiian or Other Pacific Islander000000
Black or African American8442927
White10175326
More than one race000000
Unknown or Not Reported000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CYP3A5 Expressers Without Chronic Kidney DiseaseCYP3A5 Expressers With Chronic Kidney DiseaseCYP3A5 Non-expressers Without Chronic Kidney DiseaseCYP3A5 Non-expressers With Chronic Kidney DiseaseNon-GenotypedTotal
Hispanic or Latino100001
Not Hispanic or Latino942371356
Unknown or Not Reported000000
08

Study locations

1 site
  • IU Health University Hospital
    Indianapolis, Indiana 46202, United States
09

References and documents

Publications

  • Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3. PubMed 25801146 ↗
  • Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019 Jul 8;8(7):989. doi: 10.3390/jcm8070989. PubMed 31288397 ↗
  • Gisch DL, Koyama S, Etkins J, So GC, Fehrenbach DJ, Lu JBL, Cheng YH, Ferreira RM, Rajadhyaksha E, McClara K, Asghari M, Sharfuddin AA, Dagher PC, Snell LM, Madhur MS, Polidoro RB, Desta Z, Eadon MT. Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans. JCI Insight. 2025 Nov 18;11(1):e198590. doi: 10.1172/jci.insight.198590. eCollection 2026 Jan 9. PubMed 41252210 ↗
  • So GC, Lu JBL, Koyama S, Cheng YH, Gisch DL, McClara K, Dexter PR, Sharfuddin AA, Etkins J, Tillman EM, Beamon TR, Cowsert Z, Stuart JS, Desta Z, Eadon MT. A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus. Clin Pharmacol Ther. 2025 Mar;117(3):716-723. doi: 10.1002/cpt.3504. Epub 2024 Nov 27. PubMed 39601108 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Aug 2025, 34 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 109 phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 5, 2022
StartActual
Oct 31, 2022
Primary completionActual
Aug 31, 2025
CompletionActual
Aug 31, 2025
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe AUC0-Infinity ratioRatio of tacrolimus with cannabidiol dividedTacrolimus With Cannabidiol Divided by tacrolimus aloneTacrolimus AloneTime frame: 27 days
Sep 30, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Immune cell distribution and signaling as measured by scRNA sequencingNow Cell Viability RatioTime frame: 27 days
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe AUC0-Infinity ratioRatio of tacrolimus with cannabidiol dividedTacrolimus With Cannabidiol Divided by tacrolimus aloneTacrolimus AloneTime frame: 27 days
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Immune cell distribution and signaling as measured by scRNA sequencingNow Cell Viability RatioTime frame: 27 days
    + 3 other changes: index terms, verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05490511
Lead sponsor
Indiana University
Responsible party
Michael Eadon (Associate Professor of Medicine, Indiana University) — Principal investigator
First posted
Aug 5, 2022
Start date
Oct 31, 2022
Primary completion
Aug 31, 2025
Completion
Aug 31, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Michael Eadon, MD
principal investigator · Indiana University
Zeruesenay Desta, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PNU-100480

Start the discussion